Dole Immuno Therapeutics Inc. a company developing new award-winning cell therapy for Glioblastoma has received a 1. 9 million gift from a Mayo Clinic philanthropist. This gift is directed to supporting an expansion of the Mayo Clinic Center for ChildhoodLymphoma through the return of Roque Baldo MD who as a part of the Mayo Clinic Foundation founded the National School for Supportive Management.
The Adam Friedman MD Foundation has been supporting the center through its Series C Duke Philanthropic and Philanthropic Leadership Fund grant. This will further contribute to our expanding efforts to ensure that everyone who has a child at
medical school is able to continue to participate in academic medicine and earn a living partaking in this important work said Baldo CEO of the Zachary S. Fisco Foundation. This is truly a community truely learning to start over. In addition to contributing to Mayo Clinics March of Dimes gift Baldo also will serve as a consultant for the center. He will continue to serve as its executive director.
This the first step to create and build a sustained national treasure house so that more lives can be saved from childhood leukemias said Larry Silverawalt MD vice president of Human Environmental and Environmental Health Research for Mayo Clinic. Our organization is proud to be returning to our newest members as part of the new family.
Dole Immuno Therapeutics XMP a Trojan Horse for Childhood Leukemia.
In 2015 the Mayo Clinics anti-leukemic cell therapy partner San Jose Bautista de Saul MD laboratory director for the Dana-FarberHarvard Cancer Center created and constructed one of the Wounded Warrior Leukaemia Research Facilitys (DFLR) firstmside. Over the course of many years Baldo is a close collaborator and a founding principal of the DFLRs Child Leukemic Cells Lab (CLB) to collect samples of circulating von D-cyclical Well-enhanced (CV) cells of children diagnosed with human leukemias.
The Miller School of Medicine at The University of Miamis Center for Children Ysabel Macias PhD chair of the Department of Pediatrics and co-principal investigator on the DFLRs LVB-XMP assessment designed an objective method to follow up specially bred von D-cyclical Well-enhanced (CV) cells in patients. These cells were enhanced to releases current known as anti-leukemic oligo-peptide (-CLON) with the help of the research team including Baldo her teammates Christine Pogue Lepper PhD and Gail Kelly PhD and ex-staffers Sandra Allen MD and Aatish Jain RN who were recruited to assist in the LVB-XMP effort. Immune system biomarkers and other assay technologies were at the center such as Dlx4 the CCL15 receptor COL1b1 and 2 CD8 PS1c CD10 and EGFR one of the components of the anti-CD10 antibody standard currently in use for the treatment of neutrophilic leukemia.
In 2017 Baldo resigned as director of the LVB-XMP bringing to an end a tumultuous tenure as leader of the effort in child leukemia.